Endogenous GIP ameliorates impairment of insulin secretion in proglucagon-deficient mice under moderate beta cell damage induced by streptozotocin

Diabetologia

Volumn 59, Issue 7, 2016, Pages 1533-1541

  Iida, Atsushi ^a   Seino, Yusuke ^a   Fukami, Ayako ^a   Maekawa, Ryuya ^a   Yabe, Daisuke ^b,c   Shimizu, Shinobu ^b   Kinoshita, Keita ^d   Takagi, Yusuke ^d   Izumoto, Takako ^a   Ogata, Hidetada ^a   Ishikawa, Kota ^a   Ozaki, Nobuaki ^d   Tsunekawa, Shin ^a   Hamada, Yoji ^a   Oiso, Yutaka ^a   Arima, Hiroshi ^a   Hayashi, Yoshitaka ^d  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Kobe Biotechnology Research and Human Resource Development Center   (Japan)

^c KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NAGOYA UNIVERSITY   (Japan)

Author keywords

Dipeptidyl peptidase IV; GIP; GLP 1; Glucagon; Hyperglycaemia; Insulin; Insulin secretion; Streptozotocin

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; PROGLUCAGON; STREPTOZOCIN; INSULIN;

ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL DAMAGE; CELL SURVIVAL; CONTROLLED STUDY; DIABETES MELLITUS; GENE INACTIVATION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HYPERGLYCEMIA; INSULIN DEFICIENCY; INSULIN RELEASE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; DEFICIENCY; DISEASE MODEL; EXPERIMENTAL DIABETES MELLITUS; GENETICS; KNOCKOUT MOUSE; METABOLISM; PHYSIOLOGY;

ANIMALS; APOPTOSIS; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; GASTRIC INHIBITORY POLYPEPTIDE; INSULIN; INSULIN-SECRETING CELLS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROGLUCAGON; STREPTOZOCIN;

EID: 84962675748     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-016-3935-2     Document Type: Article

References (46)

1. Ramnanan CJ, Edgerton DS, Kraft G et al (2011) Physiologic action of glucagon on liver glucose metabolism. Diabetes Obes Metab 13(Suppl 1):S118–S125
2. Müller WA, Faloona GR, Aguilar-Parada E et al (1970) Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med 283:109–115
3. Gromada J, Franklin I, Wollheim CB (2007) Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev 28:84–116
4. Furuta M, Yano H, Zhou A et al (1997) Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2. Proc Natl Acad Sci U S A 94:6646–6651
5. Gagnon J, Mayne J, Chen A et al (2011) PCSK2-null mice exhibit delayed intestinal motility, reduced refeeding response and altered plasma levels of several regulatory peptides. Life Sci 88:212–217
6. Gelling RW, Du XQ, Dichmann DS et al (2003) Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci U S A 100:1438–1443
7. Sloop KW, Cao JX-C, Siesky AM et al (2004) Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Invest 113:1571–1581
8. Hancock AS, Du A, Liu J et al (2010) Glucagon deficiency reduces hepatic glucose production and improves glucose tolerance in adult mice. Mol Endocrinol 24:1605–1614
9. Conarello SL, Jiang G, Mu J et al (2007) Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia. Diabetologia 50:142–150
10. Lee Y, Wang M-Y, Du XQ et al (2011) Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes 60:391–397
11. Omar BA, Andersen B, Hald J et al (2014) Fibroblast growth factor 21 (FGF21) and glucagon-like peptide 1 contribute to diabetes resistance in glucagon receptor-deficient mice. Diabetes 63:101–110
12. Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131–2157
13. Seino Y, Yabe D (2013) Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: incretin actions beyond the pancreas. J Diabetes Investig 4:108–130
14. Longuet C, Robledo AM, Dean ED et al (2013) Liver-specific disruption of the murine glucagon receptor produces α-cell hyperplasia: evidence for a circulating α-cell growth factor. Diabetes 62:1196–1205
15. Hayashi Y, Yamamoto M, Mizoguchi H et al (2009) Mice deficient for glucagon gene-derived peptides display normoglycemia and hyperplasia of islet alpha-cells but not of intestinal L-cells. Mol Endocrinol 23:1990–1999
16. Fukami A, Seino Y, Ozaki N et al (2013) Ectopic expression of GIP in pancreatic β-cells maintains enhanced insulin secretion in mice with complete absence of proglucagon-derived peptides. Diabetes 62:510–518
17. Miyawaki K, Yamada Y, Yano H et al (1999) Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci U S A 96:14843–14847
18. Li Y, Hansotia T, Yusta B et al (2003) Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278:471–478
19. Collombat P, Xu X, Ravassard P et al (2009) The ectopic expression of Pax4 in the mouse pancreas converts progenitor cells into alpha and subsequently beta cells. Cell 138:449–462
20. Ali S, Lamont BJ, Charron MJ et al (2011) Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis. J Clin Invest 121:1917–1929
21. Sakamoto E, Seino Y, Fukami A et al (2012) Ingestion of a moderate high-sucrose diet results in glucose intolerance with reduced liver glucokinase activity and impaired glucagon-like peptide-1 secretion. J Diabetes Investig 3:432–440
22. Nasteska D, Harada N, Suzuki K et al (2014) Chronic reduction of GIP secretion alleviates obesity and insulin resistance under high-fat diet conditions. Diabetes 63:2332–2343
23. Moffett RC, Vasu S, Flatt PR (2015) Functional GIP receptors play a major role in islet compensatory response to high fat feeding in mice. Biochim Biophys Acta 1850:1206–1214
24. Hansotia T, Baggio LL, Delmeire D et al (2004) Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of dpp-iv inhibitors. Diabetes 53:1326–1335
25. Maida A, Hansotia T, Longuet C et al (2009) Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice. Gastroenterology 137:2146–2157
26. Vasu S, Moffett RC, Thorens B et al (2014) Role of endogenous GLP-1 and GIP in beta cell compensatory responses to insulin resistance and cellular stress. PLoS One 9:e101005
27. Saltiel AR, Kahn CR (2001) Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414:799–806
28. Mitrakou A, Kelley D, Veneman T et al (1990) Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes 39:1381–1390
29. Lee Y, Shin S, Shigihara T et al (2007) Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis. Diabetes 56:1671–1679
30. Jun LS, Millican RL, Hawkins ED et al (2015) Absence of glucagon and insulin action reveals a role for the GLP-1 receptor in endogenous glucose production. Diabetes 64:819–827
31. Thorel F, Damond N, Chera S et al (2011) Normal glucagon signaling and β-cell function after near-total α-cell ablation in adult mice. Diabetes 60:2872–2882
32. Steenberg VR, Jensen SM, Pedersen J et al (2016) Acute disruption of glucagon secretion or action does not improve glucose tolerance in an insulin-deficient mouse model of diabetes. Diabetologia 59:363–370
33. Pedersen J, Ugleholdt RK, Jørgensen SM et al (2013) Glucose metabolism is altered after loss of L cells and α-cells but not influenced by loss of K cells. Am J Physiol Endocrinol Metab 304:E60–E73
34. Watanabe C, Seino Y, Miyahira H et al (2012) Remodeling of hepatic metabolism and hyperaminoacidemia in mice deficient in proglucagon-derived peptides. Diabetes 61:74–84
35. Sørensen H, Winzell MS, Brand CL et al (2006) Glucagon receptor knockout mice display increased insulin sensitivity and impaired beta-cell function. Diabetes 55:3463–3469
36. Rorsman P, Braun M (2013) Regulation of insulin secretion in human pancreatic islets. Annu Rev Physiol 75:155–179
37. Widenmaier SB, Kim S-J, Yang GK et al (2010) A GIP receptor agonist exhibits beta-cell anti-apoptotic actions in rat models of diabetes resulting in improved beta-cell function and glycemic control. PLoS One 5:e9590
38. Seino S, Shibasaki T, Minami K (2011) Dynamics of insulin secretion and the clinical implications for obesity and diabetes. J Clin Invest 121:2118–2125
39. Kim S-J, Nian C, Karunakaran S et al (2012) GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis. PLoS One 7:e40156
40. Trümper A, Trümper K, Hörsch D (2002) Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells. J Endocrinol 174:233–246
41. Ehses JA, Casilla VR, Doty T et al (2003) Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. Endocrinology 144:4433–4445
42. Heller RS, Aponte GW (1995) Intra-islet regulation of hormone secretion by glucagon-like peptide-1-(7--36) amide. Am J Physiol 269:G852–G860
43. Hörsch D, Göke R, Eissele R et al (1997) Reciprocal cellular distribution of glucagon-like peptide-1 (GLP-1) immunoreactivity and GLP-1 receptor mRNA in pancreatic islets of rat. Pancreas 14:290–294
44. Masur K, Tibaduiza EC, Chen C et al (2005) Basal receptor activation by locally produced glucagon-like peptide-1 contributes to maintaining beta-cell function. Mol Endocrinol 19:1373–1382
45. Fujita Y, Wideman RD, Asadi A et al (2010) Glucose-dependent insulinotropic polypeptide is expressed in pancreatic islet alpha-cells and promotes insulin secretion. Gastroenterology 138:1966–1975
46. Omar BA, Liehua L, Yamada Y et al (2014) Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes. Diabetologia 57:1876–1883